Do GLP-1 drugs really trap you in lifelong dependency?

What did @ritalinknermd actually say?

A board-certified obesity medicine physician with a dermatology background argued that going on and off GLP-1 medications is risky, and that "if you start, you can't stop." She made three core claims: obesity rewires your epigenome in a way that persists even after weight loss; stopping GLP-1s causes metabolic adaptation that can reduce future drug response; and GLP-1s work by resetting a genetically determined "set weight" that the brain reverts to once the drug is gone. She also predicted that retatrutide, a triple-receptor agonist, will hit the market around 2028 with roughly 24% average weight loss at 48 weeks.

The framing was aimed at patients who cycle on and off these drugs, and the advice, broadly speaking, is that continuous use is preferable to repeated stopping and starting.

Does the science back this up?

Mostly, yes, though some claims are overstated or imprecisely framed. The core argument that obesity involves persistent biological changes is well-supported. The metabolic adaptation claim is real but more nuanced than presented. The biologic resistance analogy is plausible but not directly proven for GLP-1s.

On epigenetics: a 2024 study by Hinte et al. published in Nature did show that fat cells retain obesity-associated epigenetic marks even after significant weight loss, including after bariatric surgery. That finding is legitimate and genuinely important. Where she oversimplifies is in implying this epigenetic memory directly explains why people regain weight on GLP-1s specifically, the mechanism in that context is less established.

On metabolic adaptation: when people lose weight, resting metabolic rate drops more than body composition alone would predict. This is documented in classic work by Leibel et al. (1995, New England Journal of Medicine) and more recently in Sumithran et al. (2011, NEJM), which showed appetite hormones remain dysregulated a year after caloric restriction. Whether this makes GLP-1s less effective on re-initiation is a separate question with limited direct evidence.

What did they get wrong (or right)?

The biologic resistance analogy is the weakest link here. She says stopping GLP-1s is like stopping psoriasis biologics, where you "build an inherent resistance" and need a higher dose on return. Biologic resistance in psoriasis is largely immune-mediated, driven by anti-drug antibodies. GLP-1 receptor agonists work differently, and there is no published evidence of a comparable antibody-driven resistance mechanism with semaglutide or tirzepatide. That analogy, while intuitive given her dermatology background, is not supported by clinical data and could mislead patients into thinking they have damaged their treatment options permanently.

What she got right: the weight regain data after stopping GLP-1s is real. The STEP 4 trial (Rubino et al., 2021, JAMA) showed that patients who stopped semaglutide regained two-thirds of their lost weight within a year. The clinical argument for continuity of treatment is sound. Her retatrutide data reference is also accurate, matching phase 2 results published by Jastreboff et al. (2023, NEJM).

What should you actually know?

The honest answer is that GLP-1 medications treat obesity the same way antihypertensives treat high blood pressure: they work while you take them. This is not a flaw in the drug. It reflects the biology of a chronic condition. "Once you start, you can't stop" is a dramatic framing of a more straightforward clinical reality: obesity is chronic, and its treatment typically needs to be too.

That said, some patients do maintain meaningful weight loss after stopping, and the decision to discontinue should be made with a clinician, not avoided out of fear. The concern about cycling on and off is reasonable, though the idea that you permanently blunt your future response is not firmly established in GLP-1 literature. Patients should not feel locked in by catastrophic language, but they should understand that restarting may not work as well, and that the biology does not reset cleanly.

• Stopping semaglutide is associated with significant weight regain within 12 months (Rubino et al., 2021, JAMA).
• Obesity-associated epigenetic changes persist after weight loss, but the direct clinical implications for GLP-1 re-treatment are not yet clear.
• There is no published evidence of antibody-mediated GLP-1 resistance analogous to biologic resistance in psoriasis.